Arcadia Biosciences, Inc. (RKDA) Forms $4.84 Double Bottom; Yume (YUME) Has 1.45 Sentiment

February 15, 2018 - By Evgen Dobrzhanskiy

YuMe, Inc., together with its subsidiaries, provides digital video brand advertising solutions in the United States and internationally. The company has market cap of $129.30 million. The companyÂ’s proprietary technologies serve the needs of brand advertisers and enable them to find and target audiences across a range of Internet-connected devices and digital media properties. It has a 14.98 P/E ratio. It offers software to monetize professionally-produced content and applications for digital media properties.

Arcadia Biosciences, Inc. (RKDA) formed double bottom with $4.55 target or 6.00% below today’s $4.84 share price. Arcadia Biosciences, Inc. (RKDA) has $10.33M valuation. The stock decreased 4.72% or $0.24 during the last trading session, reaching $4.84. About 677 shares traded. Arcadia Biosciences, Inc. (NASDAQ:RKDA) has declined 43.32% since February 15, 2017 and is downtrending. It has underperformed by 60.02% the S&P500.

Analysts await Arcadia Biosciences, Inc. (NASDAQ:RKDA) to report earnings on March, 14. They expect $-0.10 earnings per share, up 23.08% or $0.03 from last year’s $-0.13 per share. After $-0.11 actual earnings per share reported by Arcadia Biosciences, Inc. for the previous quarter, Wall Street now forecasts -9.09% EPS growth.

Among 2 analysts covering Arcadia Biosciences (NASDAQ:RKDA), 0 have Buy rating, 0 Sell and 2 Hold. Therefore 0 are positive. Arcadia Biosciences had 2 analyst reports since May 12, 2017 according to SRatingsIntel. Piper Jaffray maintained Arcadia Biosciences, Inc. (NASDAQ:RKDA) rating on Friday, July 21. Piper Jaffray has “Hold” rating and $100 target. The firm has “Neutral” rating given on Friday, May 12 by PiperJaffray.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our daily email newsletter.





Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: